Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 10, 2007

AnaSpec Offers Novel Beta-Amyloid Peptides

  • Because of a C-terminus sequence composed primarily of hydrophobic amino acids, beta-amyloid peptides with sequences 1-44 to 1-48 have not been commercially available. AnaSpec now offers beta-amyloid peptides for sequences 1-44, 1-45, 1-46, 1-47, 1-48, and 1-49.

    "With the successful commercialization of these longer beta-amyloid peptides, we are pleased to offer an even broader selection of amyloid-related products for our customers," states AnaSpec president, Anita Hong.

    Amyloid Precursor Protein is predominantly processed by alpha-secretase, while a small amount is processed by beta-secretase, which produces a 99-amino acid C-terminal fragment, C99. Subsequent cleavages of C99 by gamma-secretase produce a 4-kD (beta-amyloid) protein. The 4-Kd consists of beta-amyloids that are 39–42 amino acids in length, with beta-amyloid 1-42 being the major component of amyloid plaques that accumulate in neurons of Alzheimer's diseased brains. Novel cleavage sites (epsilon and zeta) downstream of the gamma-cleavage site have recently been reported, which release longer beta-amyloid peptides (1-43, 1-45, 1-46 and 1-48).
     



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »